

KEY INFORMATION DOCUMENT

PURPOSE - This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Allianz Biotechnologie Share Class R (EUR)



ISIN DE000A2AMPU5

WKN A2AMPU

PRODUCT

Allianz Biotechnologie (the "Fund") is established as a Germany domiciled FCP and managed by Allianz Global Investors GmbH, part of group Allianz Global Investors. This Fund is authorised and regulated by Bundesanstalt für Finanzdienstleistungsaufsicht in Germany (www.bafin.de).

Allianz Global Investors GmbH, a German capital management company, is authorised and regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) in Germany (www.bafin.de). For more information on this Fund, please refer to <https://regulatory.allianzgi.com> or call +49 69 24431 140.

This key information document is accurate as at 29.11.2023.

WHAT IS THIS PRODUCT?

TYPE

This Fund is a UCITS according to European Directive 2009/65/EC.

TERM

The Fund has been set-up for an indefinite period of time. In accordance with the Fund's rules, the assets belonging to the Fund are owned jointly by the Fund's unitholders. The Management Company may terminate the Fund's management according to the Fund's rules. In this case, the Management Company / the Fund's appointed depository will either entrust its management to another management company or the depository will liquidate the Fund and distribute the proceeds to the Fund's unitholders.

You may redeem shares of the Fund usually on each business day. We usually distribute the income of the Fund on a yearly basis. The management company may suspend redemption if exceptional circumstances make this appear necessary, taking into account the interests of the investors, or limit redemption if the investors' redemption requests reach a predefined threshold above which the redemption requests can no longer be executed in the interests of the investors as a whole.

OBJECTIVES

The Fund aims to generate long-term capital growth.

We invest at least 70% of the Fund's assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund's assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund's assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund's assets may be invested in target funds (UCITS and/or UCI).

We pursue an active management approach aimed at outperforming the benchmark. The benchmark index is used for

performance measurement purposes only and not for the purpose of portfolio composition. The majority of the securities included in the Fund are also included in the benchmark index. The fund manager has the flexibility to invest in securities that are not included in the benchmark index. When selecting and weighting the Fund's assets, Fund Management may deviate significantly from the securities included in the benchmark index, as well as their corresponding weightings.

Benchmark: NASDAQ Biotechnology Price (in EUR).

Derivatives may be used to offset exposure to price fluctuations (hedging), to take advantage of price differences between two or more markets (arbitrage) or to multiply gains although it may also multiply losses (leverage). A derivative is a financial instrument whose value depends - not necessarily 1:1 - on the development of one or more underlying assets (e.g., securities or interest rates).

SFDR Category – Article 6 (a financial product that does not consider the EU criteria for environmentally sustainable economic activities)

OTHER INFORMATION

Depository: State Street Bank International GmbH

For more details about the Fund, visit the regulatory information website at <https://regulatory.allianzgi.com>. Select your country of residence and your Fund on the website and view the regulatory information or documents provided, which include the following topics and information:

- Fund's statutory sales documents (including prospectus, latest annual and semi-annual reports) in English and German. The statutory sales documents are also available free of charge in paper form upon request from Allianz Global Investors GmbH, Bockenheimer Landstraße 42-44, D-60323 Frankfurt/Main, Germany

The person advising on or selling you this Fund may charge you other costs. If so, this person will provide you with information

about these costs and how they affect your investment.

COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the Fund and how well the Fund does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the Fund performs as shown in the moderate scenario
- 10,000 EUR is invested

	If you exit after 1 year	If you exit after 5 years
Total costs	248 EUR	1,708 EUR
Annual cost impact (*)	2.5 %	2.5 % each year

(*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 9.6 % before costs and 7.1 % after costs.

COMPOSITION OF COSTS

One-off costs upon entry or exit		If you exit after 1 year:
Entry costs	We do not charge an entry fee.	0 EUR
Exit costs	We do not charge an exit fee for this Fund, but the person selling you the Fund may do so.	0 EUR
Ongoing costs		
Management fees and other administrative or operating costs	1.17 % of the value of your investment per year. This is an estimate based on actual costs over the last year.	117 EUR
Transaction costs	1.31 % of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Fund. The actual amount will vary depending on how much we buy and sell.	131 EUR
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this Fund.	0 EUR

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MONEY OUT EARLY?

Recommended holding period: 5 years

Due to its investment strategy, the Fund's value may vary considerably over the short time. You should therefore stay invested for at least 5 years to profit from gains on the longer term. If you disinvest earlier, there is a higher risk that you might get back only poor returns, or not even the sum you invested. The

Fund is open-ended which means you can redeem money back at every NAV calculation and without having to pay penalties. If applicable to your Fund you will pay the exit fees only. The detailed procedure to redeem from the Fund is described in the Prospectus.

HOW CAN I COMPLAIN?

Please contact the complaint management team using the details below. They will oversee the processing of the complaint by the different lines of business involved until its resolution and will ensure that potential conflicts of interest are identified and handled appropriately.

Allianz Global Investors GmbH, Compliance, Bockenheimer Landstrasse 42-44, D-60323 Frankfurt am Main, Germany
Phone number: +49 69 24431 140
Website: <https://regulatory.allianzgi.com/en/investors-rights>
Email address: investorrightsandcomplaints@allianzgi.com

OTHER RELEVANT INFORMATION

Pre-Contractual/Website Disclosure SFDR Information can be found using the link <https://regulatory.allianzgi.com/en/sfdr>

The Fund is subject to tax laws and regulations in Germany, and this might have an impact on your personal tax position. For

further advice please contact your tax advisor. Allianz Global Investors GmbH may be held liable solely based on any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund.